# A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation

> **NCT01797952** · PHASE3 · WITHDRAWN · sponsor: **All India Institute of Medical Sciences**

## Conditions studied

- Oral Mucositis in Patients Undergoing HSCT

## Interventions

- **DRUG:** Lactobacillus CD 2
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01797952
- **Lead sponsor:** All India Institute of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-11
- **Primary completion:** 2016-10
- **Final completion:** 2016-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI was away on sabbatical for 2 years.Protocol is being revised before starting the study.
- **Last updated:** 2016-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01797952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01797952, "A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01797952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*